Published in Immunol Rev on October 01, 2002
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med (2009) 1.47
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun (2007) 1.28
Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A (2004) 1.21
Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung (2009) 1.12
miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol (2010) 1.10
Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells. J Transl Med (2004) 1.02
B-Raf specific antibody responses in melanoma patients. BMC Cancer (2004) 0.96
Clinical development of Listeria monocytogenes-based immunotherapies. Semin Oncol (2012) 0.95
T-cell clonotypes in cancer. J Transl Med (2004) 0.91
Adaptive immunity does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer. J Immunol (2013) 0.89
MAGE proteins regulate KRAB zinc finger transcription factors and KAP1 E3 ligase activity. Arch Biochem Biophys (2014) 0.81
Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci U S A (2004) 0.80
Myeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine model. Oncol Lett (2015) 0.80
Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer. Int J Clin Exp Pathol (2015) 0.78
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines. Cancers (Basel) (2011) 0.77
Modelling lymphoma therapy and outcome. Bull Math Biol (2013) 0.76
Advances in cellular therapy for the treatment of thyroid cancer. J Oncol (2010) 0.76
Generating long-lived CD8(+) T-cell memory: Insights from epigenetic programs. Eur J Immunol (2016) 0.75
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med (2003) 7.86
Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol (2006) 6.82
Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol (2004) 3.23
Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J (2004) 2.94
Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol (2009) 2.71
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 2.63
An antigenic peptide produced by peptide splicing in the proteasome. Science (2004) 2.20
Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev (2002) 2.18
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. Am J Respir Crit Care Med (2011) 1.78
Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med (2005) 1.75
Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci U S A (2010) 1.70
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 1.65
Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res (2005) 1.57
Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res (2010) 1.56
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Immunol (2007) 1.56
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med (2005) 1.55
A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res (2002) 1.51
Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. Ann Thorac Surg (2003) 1.49
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity (2008) 1.48
Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J Immunol (2005) 1.48
Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res (2012) 1.41
Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Mol Cell Biol (2004) 1.39
Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg (2010) 1.39
Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J Immunol (2006) 1.36
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res (2006) 1.33
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
The development of bronchopleural fistula in lung cancer patients after major surgery: 31 years of experience with 19 cases. Anticancer Res (2011) 1.30
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res (2011) 1.29
A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res (2010) 1.25
Comparison of stable human Treg and Th clones by transcriptional profiling. Eur J Immunol (2009) 1.23
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer (2009) 1.23
Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2010) 1.22
Crystal structure of the IL-22/IL-22R1 complex and its implications for the IL-22 signaling mechanism. FEBS Lett (2008) 1.22
Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer (2011) 1.21
Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A (2004) 1.21
Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. Int J Cancer (2003) 1.18
Successful extirpation of thoracic pleural lipoma by single-port thoracoscopic surgery. Asian J Surg (2011) 1.18
Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol (2002) 1.18
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer (2008) 1.18
Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res (2008) 1.18
MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res (2004) 1.17
The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res (2009) 1.14
Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer (2009) 1.13
Tracheobronchopathia osteochondroplastica occurring in a subsegmental bronchus and causing obstructive pneumonia. Ann Thorac Surg (2005) 1.11
Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood (2008) 1.11
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J Med Chem (2011) 1.10
Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett (2007) 1.08
Crystal structure of recombinant human interleukin-22. Structure (2002) 1.08
Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol (2010) 1.08
Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer (2010) 1.08
Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol (2003) 1.07
Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol (2002) 1.07
Clostridium tertium bacteremia: contamination or true pathogen? A report of two cases and a review of the literature. Int J Infect Dis (2010) 1.07
Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells. J Biol Chem (2006) 1.07
Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol (2003) 1.05
Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother (2004) 1.04
A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol (2003) 1.04
CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation. Blood (2006) 1.04
Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res (2010) 1.03
Production of an antigenic peptide by insulin-degrading enzyme. Nat Immunol (2010) 1.02
Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion. Eur J Immunol (2005) 1.02
Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci (2007) 1.01
Simple prophylactic fixation for lung torsion. Ann Thorac Surg (2010) 1.01
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res (2009) 1.00
Tumour immunology. Curr Opin Immunol (2003) 1.00